We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
20 June 2017
VISCHER advises Inthera Bioscience AG, a Zurich based biopharmaceutical company, developing first-in-class targeted small molecule therapies for solid tumors.
Inthera Bioscience employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs). The company’s drug discovery programs are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development.
The VISCHER team includes Christian Wyss (Partner), Dania Salvisberg-Schneider (Senior Associate), both Corporate and Nadia Tarolli (Partner), Tax.
Categories: Corporate and commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Deals & Cases
Attorney at Law, Swiss Certified Tax Expert (2008)
Attorney at Law
Datum: 29. Februar 2024 (Basel) & 7. März 2024 (Zürich) Veranstalter: VISCHER AG Veranstaltungsort...
T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has...
Veranstalter: Basel Area Veranstaltungsort: Markthalle, Viaduktstrasse 10, 4051 Basel